The use of biological and targeted synthetic basic anti-inflammatory drugs in elderly patients with rheumatoid arthritis: for or against

Author:

Pykhtina V. S.1ORCID,Machekhina L. V.1ORCID,Meshkov A. D.1ORCID,Strazhesko I. D.1ORCID

Affiliation:

1. Russian Gerontology Clinical Research Center of Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation

Abstract

Due to the global aging of the population and increasing life expectancy, the population of elderly patients with rheumatoid arthritis is growing, both due to patients with onset after 60 years of age (EORA), and elderly patients in whom the disease started at a young age. Treatment of such patients is associated with a number of difficulties, which is associated with the characteristics of the aging of the immune system and the body as a whole, and the burden of comorbid conditions. Elderly patients, unlike young ones, have a higher risk of developing adverse events when prescribed both basic and biological drugs. These features lead to a more “gentle” treatment strategy for elderly patients, limited use of adequate doses of basic drugs and a low number of prescriptions of biological drugs among doctors. This article provides current data on the safety and effectiveness of the use of biological and targeted synthetic disease-modifying anti-inflammatory drugs in elderly patients with rheumatoid arthritis.

Publisher

Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology

Reference99 articles.

1. Safiri S, Kolahi A, Hoy D, Smith E, Bettampadi D, Mansournia MEA. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis 2019;215920. https://doi. org/10.1136/annrheumdis-2019-215920.

2. Krams T, Ruyssen-Witrand A, Nigon D, Degboe Y, Tobon G, Fautrel B, Berenbaum F, Cantagrel A, Constantin A. Effect of age at rheumatoid arthritis onset on clinical, radiographic, and functional outcomes: The ESPOIR cohort. Joint Bone Spine. 2016 Oct;83(5):511-5. doi: 10.1016/j.jbspin.2015.09.010. Epub 2016 Mar 15. PMID: 26992954.

3. Rasch E, Hirsch R, Paulose-Ram R, Hochberg M. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003;48:917–26. https://doi.org/10.1002/ art.10897.

4. Marín JS, Mazenett-Granados EA, Salazar-Uribe JC, Sarmiento M, Suárez JF, Rojas M, Munera M, Pérez R, Morales C, Dominguez JI, Anaya JM. Increased incidence of rheumatoid arthritis after COVID-19. Autoimmun Rev. 2023 Oct;22(10):103409. doi: 10.1016/j.autrev.2023.103409. Epub 2023 Aug 18. PMID: 37597602.

5. Ke Y, Dai X, Xu D, Liang J, Yu Y, Cao H, Chen W, Lin J. Features and Outcomes of Elderly Rheumatoid Arthritis: Does the Age of Onset Matter? A Comparative Study From a Single Center in China. Rheumatol Ther. 2021 Mar;8(1):243-254. doi: 10.1007/s40744-020-00267-8. Epub 2020 Dec 14. PMID: 33315188; PMCID: PMC7991049.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3